150 related articles for article (PubMed ID: 37392903)
41. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.
Tsai TH; Wu SG; Hsieh MS; Yu CJ; Yang JC; Shih JY
Lung Cancer; 2015 May; 88(2):208-14. PubMed ID: 25773866
[TBL] [Abstract][Full Text] [Related]
42. Morphological and molecular approach to synchronous non-small cell lung carcinomas: impact on staging.
Schneider F; Derrick V; Davison JM; Strollo D; Incharoen P; Dacic S
Mod Pathol; 2016 Jul; 29(7):735-42. PubMed ID: 27080983
[TBL] [Abstract][Full Text] [Related]
43. Genes associated with increased brain metastasis risk in non-small cell lung cancer: Comprehensive genomic profiling of 61 resected brain metastases versus primary non-small cell lung cancer (Guangdong Association Study of Thoracic Oncology 1036).
Wang H; Ou Q; Li D; Qin T; Bao H; Hou X; Wang K; Wang F; Deng Q; Liang J; Zheng W; Wu X; Wang X; Shao YW; Mou Y; Chen L
Cancer; 2019 Oct; 125(20):3535-3544. PubMed ID: 31287555
[TBL] [Abstract][Full Text] [Related]
44. Molecular analysis in cytological samples obtained by endobronchial or oesophageal ultrasound guided needle aspiration in non-small cell lung cancer.
Centeno C; Serra Mitja P; Avila M; Carcereny E; Muñoz-Mármol AM; Moran T; Castellà E; Sanz-Santos J; García Olivé I; Ramirez Serrano JL; Rosell Gratacos A; Andreo García F
Pulmonology; 2022; 28(1):28-33. PubMed ID: 32507497
[TBL] [Abstract][Full Text] [Related]
45. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
[TBL] [Abstract][Full Text] [Related]
46. Concurrent classic driver oncogenes mutation with ROS1 rearrangement predicts superior clinical outcome in NSCLC patients.
Li D; Jiang H; Jin F; Pan L; Xie Y; Zhang L; Li C
Genes Genomics; 2023 Jan; 45(1):93-102. PubMed ID: 36445572
[TBL] [Abstract][Full Text] [Related]
47. Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers.
Tan AC; Itchins M; Khasraw M
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32093103
[TBL] [Abstract][Full Text] [Related]
48. Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma.
Ekin Z; Nart D; Savaş P; Veral A
Balkan Med J; 2021 Sep; 38(5):287-295. PubMed ID: 34558414
[TBL] [Abstract][Full Text] [Related]
49. Determinants of survival in advanced non--small-cell lung cancer in the era of targeted therapies.
Bauml J; Mick R; Zhang Y; Watt CD; Vachani A; Aggarwal C; Evans T; Langer C
Clin Lung Cancer; 2013 Sep; 14(5):581-91. PubMed ID: 23827517
[TBL] [Abstract][Full Text] [Related]
50. Identification of
Reguart N; Teixidó C; Giménez-Capitán A; Paré L; Galván P; Viteri S; Rodríguez S; Peg V; Aldeguer E; Viñolas N; Remon J; Karachaliou N; Conde E; Lopez-Rios F; Nadal E; Merkelbach-Bruse S; Büttner R; Rosell R; Molina-Vila MA; Prat A
Clin Chem; 2017 Mar; 63(3):751-760. PubMed ID: 28073897
[TBL] [Abstract][Full Text] [Related]
51. Front-line therapy for brain metastases and non-brain metastases in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: a network meta-analysis.
Zhu Y; Liu C; Xu Z; Zou Z; Xie T; Xing P; Wang L; Li J
Chin Med J (Engl); 2023 Nov; 136(21):2551-2561. PubMed ID: 37160733
[TBL] [Abstract][Full Text] [Related]
52. Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice.
Sun L; Zhang Q; Luan H; Zhan Z; Wang C; Sun B
J Exp Clin Cancer Res; 2011 Mar; 30(1):30. PubMed ID: 21414214
[TBL] [Abstract][Full Text] [Related]
53. A Comprehensive Meta-Analysis of Association between EGFR Mutation Status and Brain Metastases in NSCLC.
Tan L; Wu Y; Ma X; Yan Y; Shao S; Liu J; Ma H; Liu R; Chai L; Ren J
Pathol Oncol Res; 2019 Apr; 25(2):791-799. PubMed ID: 30761450
[TBL] [Abstract][Full Text] [Related]
54. Definitive Chemoradiation and Durvalumab Consolidation for Locally Advanced, Unresectable KRAS-mutated Non-Small Cell Lung Cancer.
Guo MZ; Murray JC; Ghanem P; Voong KR; Hales RK; Ettinger D; Lam VK; Hann CL; Forde PM; Brahmer JR; Levy BP; Feliciano JL; Marrone KA
Clin Lung Cancer; 2022 Nov; 23(7):620-629. PubMed ID: 36045016
[TBL] [Abstract][Full Text] [Related]
55. Molecular alterations in non-small cell lung carcinomas of the young.
VandenBussche CJ; Illei PB; Lin MT; Ettinger DS; Maleki Z
Hum Pathol; 2014 Dec; 45(12):2379-87. PubMed ID: 25288236
[TBL] [Abstract][Full Text] [Related]
56. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
[TBL] [Abstract][Full Text] [Related]
57. Mutation status and postresection survival of patients with non-small cell lung cancer brain metastasis: implications of biomarker-driven therapy.
Shah PP; Franke JL; Medikonda R; Jackson CM; Srivastava S; Choi J; Forde PM; Brahmer JR; Ettinger DS; Feliciano JL; Levy BP; Marrone KA; Naidoo J; Redmond KJ; Kleinberg LR; Lim M
J Neurosurg; 2022 Jan; 136(1):56-66. PubMed ID: 34087798
[TBL] [Abstract][Full Text] [Related]
58. Molecular analysis of peripheral non-squamous non-small cell lung cancer sampled by radial EBUS.
Guisier F; Salaün M; Lachkar S; Lamy A; Piton N; Obstoy B; Sabourin JC; Thiberville L
Respirology; 2016 May; 21(4):718-26. PubMed ID: 27099101
[TBL] [Abstract][Full Text] [Related]
59. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
Metro G; Chiari R; Bennati C; Cenci M; Ricciuti B; Puma F; Flacco A; Rebonato A; Giannarelli D; Ludovini V; Bellezza G; Ferolla P; Minotti V; Crinò L
Clin Lung Cancer; 2014 Jan; 15(1):86-92. PubMed ID: 24139827
[TBL] [Abstract][Full Text] [Related]
60. Prognostic analysis of patients with non-small cell lung cancer harboring exon 19 or 21 mutation in the epidermal growth factor gene and brain metastases.
Wang J; Liu Z; Pang Q; Zhang T; Chen X; Er P; Wang Y; Wang P; Wang J
BMC Cancer; 2020 Sep; 20(1):837. PubMed ID: 32883221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
